Calian Group Ltd. Stock

Equities

CGY

CA12989J1084

Business Support Services

Market Closed - Toronto S.E. 15:59:50 2024-04-26 EDT 5-day change 1st Jan Change
55.31 CAD +0.16% Intraday chart for Calian Group Ltd. +0.84% -3.46%
Sales 2024 * 770M 563M Sales 2025 * 821M 600M Capitalization 656M 480M
Net income 2024 * 27M 19.75M Net income 2025 * 35M 25.61M EV / Sales 2024 * 0.9 x
Net Debt 2024 * 37.6M 27.51M Net Debt 2025 * 5.3M 3.88M EV / Sales 2025 * 0.81 x
P/E ratio 2024 *
24.4 x
P/E ratio 2025 *
12.8 x
Employees 4,400
Yield 2024 *
2.02%
Yield 2025 *
2.02%
Free-Float 99.38%
More Fundamentals * Assessed data
Dynamic Chart
Calian Group Wins $17 Million, 3-Year Contract for Military Medical Training Program with Canadian Armed Forces MT
Calian Group Brief: Says Won $23 Million Contract for New Military Medical Training Program with the Canadian Armed Forces MT
Calian Group Ltd. Wins $23 Million Contract for New Military Medical Training Program with the Canadian Armed Forces CI
Calian Group Brief: Appointing Valerie Travain-Milone as President, Advanced Technologies (AT) MT
Calian Announces the Appointment of Valérie Travain-Milone as President, Advanced Technologies CI
Correction: -- Calian Group Brief: Says to Deliver Spectrum Interference Simulation Technology for the Canadian Space Agency MT
Calian Group Says to Deliver Spectrum Interference Simulation Technology for the Canadian Space Agency MT
Calian Group and MDA Brief: Says to Deliver Spectrum Interference Simulation Technology for the Canadian Space Agency MT
Calian Group Ltd. to Deliver Spectrum Interference Simulation Technology for the Canadian Space Agency CI
North American Morning Briefing : Stock Futures Rise Ahead of Powell's Testimony DJ
Calian Group and MDA Brief: Calian Says "Strengthens Nuclear Capability" with Acquisition of MDA Ltd. Nuclear Assets MT
Calian Group Ltd. acquired Assets And Nuclear Services of MDA Ltd. CI
Calian Group Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate MT
Calian Group Brief: Says Won Contract to Support Clinical Trial for ZYUS Life Sciences' Lead Drug Product Candidate MT
Calian Group Ltd. Wins Contract to Support Clinical Trial for Zyus Life Sciences? Lead Drug Product Candidate CI
More news
1 day+0.16%
1 week+0.84%
Current month-2.62%
1 month-2.69%
3 months-3.10%
6 months+12.40%
Current year-3.46%
More quotes
1 week
54.75
Extreme 54.75
55.85
1 month
54.18
Extreme 54.18
60.18
Current year
53.88
Extreme 53.88
61.24
1 year
46.27
Extreme 46.27
64.88
3 years
46.27
Extreme 46.27
72.11
5 years
0.00
Extreme 0
72.11
10 years
0.00
Extreme 0
72.11
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 10-09-30
Director of Finance/CFO - 19-02-28
Chief Tech/Sci/R&D Officer - 22-09-30
Members of the board TitleAgeSince
Director/Board Member 66 86-12-31
Director/Board Member 40 20-12-31
Chief Executive Officer 59 10-09-30
More insiders
Date Price Change Volume
24-04-26 55.31 +0.16% 5,782
24-04-25 55.22 -0.05% 2,137
24-04-24 55.25 +0.45% 2,695
24-04-23 55 -0.94% 5,875
24-04-22 55.52 +1.22% 4,033

Delayed Quote Toronto S.E., April 26, 2024 at 03:59 pm

More quotes
Calian Group Ltd. is a diverse solutions company. The Company is engaged in providing healthcare, communications, learning and cybersecurity products and services. It provides business services and solutions to both industry and government customers in the areas of health, learning, defense, security, aerospace, engineering, and information technology (IT). Its Advanced Technologies segment is a supplier of technical solutions, services and products to the aerospace and defense, satellite, wired and terrestrial wireless, agricultural technology, and nuclear industries. The Health segment delivers healthcare and digital health solutions. The ITCS segment includes on-demand resourcing, IT and cybersecurity consulting, managed services, and software as a service. Its Learning segment provides training as a service, emergency management solutions, and custom training solutions. It also offers a full suite of services from design, installation and teleport services to satellite operations.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
55.31 CAD
Average target price
76.25 CAD
Spread / Average Target
+37.86%
Consensus